Kit Gene in Endometrial Carcinoma: An Immunohistochemical and Mutational Analysis. Issue 2 (1st January 2011)

• Record Type: Journal Article
• Authors: Vandenput, Ingrid; Debiec-Rychter, Maria; Capoen, An; Verbist, Godelieve; Vergote, Ignace; Moerman, Philippe; Amant, Frédéric
• Is Part Of: International journal of gynecological cancer. Volume 21:Issue 2(2011)
• Page Start: 203
• Page End: 205
• Publication Date: 2011-01-01
• Subjects: KIT gene -- Immunohistochemistry -- Mutation analysis -- Endometrial cancer -- Targeted therapy; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0b013e3182055c94
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Because the outcome of recurrent disease of endometrial carcinoma is cumbersome, the development of target treatment strategies is critical. We evaluated KIT, a receptor tyrosine kinase, to determine a potential role for imatinib mesylate in the treatment of endometrial carcinoma. Materials and Methods: Immunohistochemical analysis for KIT expression was performed on paraffin sections from 45 patients: 30 primary and 15 recurrent tumors. Fifteen primary cases were available for mutation analysis. Results: Histopathological distribution of paraffin-embedded tissue was as follows: 30 type I and 15 type II endometrial carcinoma. Histopathological distribution of fresh-frozen tissue was as follows: 8 type I and 7 type II. Cases did not show KIT expression or mutations in mutational hotspot exons of KIT gene. Conclusions: On the basis of the absence of KIT expression or mutations, endometrial carcinoma is unlikely to respond to imatinib mesylate.